IDH2 and cholangiocarcinoma: Of note, the first precision oncology-based randomized phase III study in patients with iCCA harboring IDH1 mutations treated with the IDH-inhibitor ivosidenib reported promising data, meeting the primary endpoint (improved progression-free survival) and highlighting the importance of accurate genetic testing in CCA [34,35].